CAP Les Corts
- Address
- C/ Mejia Lequerica, 1, 08028 Barcelona, Spain
CAP Les Corts - Primary Care Clinical Research Center
CAP Les Corts is a primary care research center with expertise in conducting ambulatory clinical trials across infectious diseases and cardiovascular prevention. The center specializes in evaluating novel therapeutic interventions in outpatient populations, focusing on early intervention strategies for high-risk patients.
- COVID-19 antiviral therapies in high-risk outpatient populations
- Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
- Lipid-lowering therapies and major adverse cardiovascular event (MACE) reduction
The center's research portfolio demonstrates a commitment to studying preventive medicine and early treatment approaches. Their work encompasses evaluation of novel agents such as inclisiran for cardiovascular risk reduction and bemnifosbuvir for COVID-19 management, with particular emphasis on preventing hospitalizations and major clinical outcomes in community-based settings. This focus positions CAP Les Corts as a key site for pragmatic trials that bridge primary care practice and advanced therapeutic research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CAP Les Corts
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Bemnifosbuvir Hemisulfate Efficacy and Safety in High-Risk COVID-19 Outpatients: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial | Atea Pharmaceuticals Inc. | Phase III | Not Recruiting | Mar 2023 | May 2024 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 2 | Unknown | 2023-09-04 | 2023-09-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.